ClinicalTrials.gg
Status unknownNCT01811368Updated Nov 30, 2022

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

A Phase 2 interventional study of rituximab and ibritumomab tiuxetan in Refractory Non Hodgkin Lymphoma and Relapsed Non Hodgkin Lymphoma, sponsored by Joseph Tuscano. Status unknown at 1 site in United States. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Joseph Tuscano · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin — none open to participants now, none under way, none of them phase 3. ibritumomab tiuxetan · Lymphoma, Non-Hodgkin.

Planned enrollment
11th of 17
20 · median 28
Started
2013
the only one that year
Phase 2
10 of 18
none open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Joseph Tuscano

Among the 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin, this one is the 11th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2013, is one of 10 in phase 2, and was the 18th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

About ibritumomab tiuxetan

ibritumomab tiuxetan: first FDA approval 2002 (ZEVALIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing ibritumomab tiuxetan in Lymphoma, Non-Hodgkin as a file.
02

Study summary

This phase II trial studies how well ibritumomab tiuxetan before donor peripheral blood stem cell transplant works in treating patients with relapsed or refractory non-Hodgkin lymphoma. Giving rituximab, antithymocyte globulin, and total-lymphoid irradiation (TLI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. Also, radiolabeled monoclonal antibodies, such as ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving rituximab, antithymocyte globulin, and TLI before the transplant together with cyclosporine and mycophenolate mofetil after the transplant may stop this from happening. Giving a radiolabeled monoclonal antibody before a donor peripheral blood stem cell transplant may be an effective treatment for non-Hodgkin lymphoma.

Read the detailed description

PRIMARY OBJECTIVES:

I. To measure the response conversion (progressive disease [PD]/stable disease [SD] to partial response [PR] and complete response [CR]).

SECONDARY OBJECTIVES:

I. To assess the time to engraftment/chimerism. II. To assess the rate of acute and chronic graft-versus-host disease (GVHD). III. To assess toxicity. IV. To determine the overall survival. V. To investigate immune functional and phenotypic analysis. VI. To measure two year event free survival (EFS).

OUTLINE:

CONDITIONING REGIMEN: Patients receive rituximab intravenously (IV) on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1.

TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant (PBSCT) on day 0.

GVHD PROPHYLAXIS: Patients receive cyclosporine orally (PO) twice daily (BID) or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28.

After completion of study treatment, patients are followed up periodically.

03

Conditions studied

  • Refractory Non Hodgkin Lymphoma
  • Relapsed Non Hodgkin Lymphoma
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed cluster of differentiation (CD)20+ non-Hodgkin's lymphoma (NHL) (included in this category are follicular grade I, II, III, marginal zone, mantle cell, diffuse large B cell, small lymphocytic lymphoma) and CD20+ Hodgkin's disease for which standard curative therapy does not exist or is no longer effective
  • Patients must have had at least one prior chemotherapeutic regimen; alone and local radiation do not count as regimens; radiotherapy must have been completed at least 4 weeks prior to entry into the study; Rituxan alone does not count as a regimen; however, Bexxar or Zevalin (ibritumomab tiuxetan) do and patients must have completed radioimmunotherapy (RIT) > 12 months prior to enrollment
  • performance status of ≥ 60%
  • of greater than 3 months
  • Total within institutional normal limits
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 2.5 times institutional
  • Creatinine within normal institutional limits OR >= 60 ml/min/1.73 m\^2 for patients with creatinine levels above institutional normal
  • Blood counts no restrictions
  • Patients who had anything less than a CR (PR, SD or progressive disease) to their last salvage regimen
  • Ability to understand and the willingness to sign a written document
  • Patients fit for non-myeloablative transplantation or best treatment that have an available matched (9/10 or better) related or unrelated donor
  • Patients who are considered rituximab refractory (defined as progression within 6 months of their last rituximab-containing regimen)

Exclusion criteria

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study, rituximab within three months (unless there is evidence of progression), or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier are excluded; this does not include the use of which may continue until two days prior to enrollment
  • Patients may not be receiving any other agents
  • Failure to obtain insurance/payment authorization for Zevalin, unless the subject agrees to cover the cost
  • Patients with known active , other neurological disorders/dysfunction or a history of seizure disorder, or other neurological dysfunction should be excluded from this clinical trial because of their poor prognosis
  • Patients who have an uncontrolled infection (presumed or documented) with progression after appropriate therapy for greater than one month
  • Patients with symptomatic coronary artery disease, uncontrolled congestive heart failure; is not required to be measured, however if it is measured, patient is excluded if ejection fraction is \< 30%
  • Patients requiring supplementary continuous oxygen; diffusion capacity of the lung of carbon monoxide (DLCO) is not required to be measured, however if it is measured, patient is excluded if DLCO \< 35%
  • Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function and histology, and for the degree of portal hypertension
  • Patients with any of the following liver function abnormalities will be excluded:

    • Fulminant liver failure
    • Cirrhosis with evidence of portal hypertension or bridging fibrosis
    • Alcoholic hepatitis
    • Esophageal varices
    • A history of bleeding esophageal varices
    • Hepatic encephalopathy
    • Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the
    • Ascites related to portal hypertension
    • Chronic viral hepatitis with total serum > 3 mg/dL
    • Symptomatic biliary disease
  • Pregnant women are excluded from this study
  • (HIV)-positive patients
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment (ibritumomab tiuxetan, allogeneic PBSCT)

    CONDITIONING REGIMEN: Patients receive rituximab IV on days -21 and 14, ibritumomab tiuxetan IV on day -14, TLI on days -11 to -7 and -4 to -1, and antithymocyte globulin IV over 4-6 hours on days -11 to -7. Patients also undergo TLI on days -11 to -7 and -4 to -1. TRANSPLANT: Patients undergo allogeneic PBSCT on day 0. GVHD PROPHYLAXIS: Patients receive cyclosporine PO BID or IV on days -3 to 56 with taper to 6 months and mycophenolate mofetil PO BID or IV on days 0-28.

    Biological: rituximab · Biological: ibritumomab tiuxetan · Biological: anti-thymocyte globulin · Radiation: total nodal irradiation · Procedure: peripheral blood stem cell transplantation · Procedure: allogeneic hematopoietic stem cell transplantation · Drug: cyclosporine · Drug: mycophenolate mofetil

Interventions

  • Biologicalrituximab

    Given IV

    Also known as: IDEC-C2B8, Mabthera, Rituxan

  • Given IV

    Also known as: Zevalin

  • BiologicalAntilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin

  • Radiationtotal nodal irradiation

    Undergo TLI

    Also known as: TLI, total lymphoid irradiation

  • Procedureperipheral blood stem cell transplantation

    Undergo allogeneic peripheral blood stem cell transplant

    Also known as: PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell

  • Procedureallogeneic hematopoietic stem cell transplantation

    Undergo allogeneic peripheral blood stem cell transplant

  • Given PO or IV

    Also known as: cyclosporin, cyclosporin A, CYSP, Sandimmune

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO or IV

    Also known as: Cellcept, MMF

06

What researchers measure

Primary outcomes

  1. Response conversion rate (PD/SD to PR and CR)

    Calculated along with 95% confidence intervals (CI). Logistic regression will be used to assess the impact of patient characteristics (e.g., low/high lactate dehydrogenase isoenzyme-3 \[LDH\] or immunologic correlates) on the response conversion rate.

    Time frame: Up to 60 days post-transplant

Secondary outcomes

  1. Time to engraftment/chimerism

    Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.

    Time frame: Up to 3 years

  2. Rate of acute GVHD

    Time frame: Up to day 730

  3. Rate of chronic GVHD

    Time frame: Up to day 730

  4. Overall survival

    Estimated using the method of Kaplan and Meier. Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.

    Time frame: Up to day 730

  5. EFS

    Comparison of time-to-event endpoints by important subgroups of patients will be made using the logrank test. Cox (proportional hazards) regression will be used to evaluate multivariable predictive models of time-to-event outcomes when proper.

    Time frame: 2 years

  6. Toxicities

    Toxicities as measured by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v4.0

    Time frame: Up to day 730

07

Study locations

1 site
  • University of California Davis
    Sacramento, California 95817, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2013 (actual). Primary completion is estimated for Apr 2023, 121 months after the start.

Of 170 non-industry phase 2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 111. This study's planned 121 months is above that.

Counting every sponsor, half of 220 studies reached it within 65 months; a quarter within 41 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2013
First posted
Mar 14, 2013
StartActual
Mar 12, 2013
Primary completionEst.
Apr 2023
CompletionEst.
Dec 2023
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01811368
Lead sponsor
Joseph Tuscano
Responsible party
Joseph Tuscano (Principal Investigator, University of California, Davis) — Sponsor-investigator
First posted
Mar 14, 2013
Start date
Mar 12, 2013
Primary completion
Apr 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Nov 30, 2022

Study contacts

Joseph Tuscano
principal investigator · UC Davis Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibritumomab tiuxetan

Start the discussion